BioArctic has announced that the US Patent and Trademark Office (USPTO) has granted a new drug substance patent for the antibody ABBV-0805, invented by BioArctic as a potential treatment of Parkinson's disease.
The patent will take effect on May 24, 2022, and expire in 2041, with the possibility
You have read all your free articles, to continue reading subscribe to read the rest of this content.